Bolt Biotherapeutics (NASDAQ:BOLT) versus Comera Life Sciences (NASDAQ:CMRA) Head-To-Head Survey

Bolt Biotherapeutics (NASDAQ:BOLT) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Profitability

This table compares Bolt Biotherapeutics and Comera Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-556.59%	-51.74%	-37.70%
Comera Life Sciences	N/A	N/A	N/A

Insider & Institutional Ownership

86.7% of Bolt Biotherapeutics shares are held by institutional investors. 30.9% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Bolt Biotherapeutics and Comera Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	0	5	0	0	2.00
Comera Life Sciences	0	0	0	0	N/A

Bolt Biotherapeutics presently has a consensus price target of $3.50, suggesting a potential upside of 404.40%.

Valuation and Earnings

This table compares Bolt Biotherapeutics and Comera Life Sciences’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$11.32 million	2.34	-$69.20 million	($1.66)	-0.42
Comera Life Sciences	$1.00 million	0.00	-$18.00 million	($0.49)	N/A

Comera Life Sciences has lower revenue, but higher earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bolt Biotherapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.

Summary

Comera Life Sciences beats Bolt Biotherapeutics on 5 of the 9 factors compared between the two stocks.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

About Comera Life Sciences

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.